The Beat AML Master Trial found high remission rates and promising safety with triplet therapy in patients with acute myeloid leukemia (AML), according to Ashley Yocum, PhD.

The upcoming webinar will delve into the advanced applications of Next Generation Flow™ in the analysis of Minimal Residual Disease (MRD) in Multiple Myeloma (MM). Dr. Juan Flores-Montero, a ...

Between 2008 and 2023, its oncology immunophenotyping lab saw the number of requests for flow cytometry increase from 3,000 to 8,500 per year, with samples of different types, which can add to the ...

Flow cytometry was thrust into the spotlight by the AIDS epidemic in the 1980s as it provides a quick and accurate way to count CD4 + and CD8 + T cells in HIV-infected patients.